title: Chronic myeloid leukemia with p190BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis.
authors.forename: Animesh
authors.initials: A
authors.lastname: Pardanani
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
authors.forename: Mark R
authors.initials: MR
authors.lastname: Litzow
authors.forename: Clive
authors.initials: C
authors.lastname: Zent
authors.forename: William J
authors.initials: WJ
authors.lastname: Hogan
authors.forename: Rebecca F
authors.initials: RF
authors.lastname: McClure
authors.forename: David
authors.initials: D
authors.lastname: Viswanatha
mesh_terms: D000368:Aged; D015331:Cohort Studies; D004252:DNA Mutational Analysis; D016044:Fusion Proteins, bcr-abl / Q000096:biosynthesis / Q000235:genetics*; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects / Q000235:genetics; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D017434:Protein Structure, Tertiary; D011505:Protein-Tyrosine Kinases / Q000096:biosynthesis / Q000235:genetics*
chemical_list: D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl